CoChat

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial

Open access
Lim, Myong Cheol, Chang, Suk-Joon, Park, Boram, Yoo, Heon Jong, Yoo, Chong Woo, Nam, Byung Ho, Park, Sang-Yoon, HIPEC for Ovarian Cancer Collaborators, Seo, Sang-Soo, Kang, Sokbom, Yun, Jung Yeon, Cho, Dae-Soon, Kim, Sun Ho, Kim, Tae-Sung, Park, Sung Sil, Lee, Dong Woon, Park, Sung Chan, Park, Hyeong Min, Han, Sung-Sik, Kim, Seoung Hoon, Yang, Hee Chul, Kim, Moon Soo, Lee, Jong Mog, Eom, Bang Wool, Kim, Young Il, Yoon, Hong Man, Choi, Il Ju, Kim, Sung Han, Joung, Jae Young, Seo, Ho Kyung, Joo, Jung Nam, Song, Yong Jung, Park, Sae Hyun, Jung, Dae Chul, Kim, Min Jung, Park, Ji Won, Jeong, Seung-Yong, Yun, Young Ho, Park, Sohee, Bristow, Robert E · 2022 · JAMA Surgery
Cited by 221

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Importance: Ovarian cancer has the highest mortality rate among gynecologic malignant tumors. Data are lacking on the survival benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with ovarian cancer who underwent primary or interval cytoreductive surgery. Objective: To assess the clinical benefit of HIPEC after primary or interval maximal cytoreductive surgery in women with stage III or IV primary advanced ovarian cancer. Design, Setting, and Participants: In this single-blind randomized clinical trial performed at 2 institutions in South Korea from March 2, 2010, to January 22, 2016, a total of 184 patients with stage III or IV ovarian cancer with residual tumor size less than 1 cm were randomized (1:1) to a HIPEC (41.5 °C, 75 mg/m2 of cisplatin, 90 minutes) or control group. The primary end point was progression-free survival. Overall survival and adverse events were key secondary end points. The date of the last follow-up was January 10, 2020, and the data were locked on February 17, 2020. Exposures: Hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. Main Outcomes and Measures: Progression-free and overall survival. Results: Of the 184 Korean women who underwent randomization, 92 were randomized to the HIPEC group (median age, 52.0 years; IQR, 46.0-59.5 years) and 92 to the control group (median age, 53.5 years; IQR, 47.5-61.0 years). After a median follow-up of 69.4 months (IQR, 54.4-86.3 months), median progression-free survival was 18.8 months (IQR, 13.0-43.2 months) in the control group and 19.8 months (IQR, 13.7-55.4 months) in the HIPEC group (P = .43), and median overall survival was 61.3 months (IQR, 34.3 months to not reported) in the control group and 69.5 months (IQR, 45.6 months to not reported) in the HIPEC group (P = .52). In the subgroup of interval cytoreductive surgery after neoadjuvant chemotherapy, the median progression-free survival was 15.4 months (IQR, 10.6-21.1 months) in the control group and 17.4 months (IQR, 13.8-31.5 months) in the HIPEC group (hazard ratio for disease progression or death, 0.60; 95% CI, 0.37-0.99; P = .04), and the median overall survival was 48.2 months (IQR, 33.8-61.3 months) in the control group and 61.8 months (IQR, 46.7 months to not reported) in the HIPEC group (hazard ratio, 0.53; 95% CI, 0.29-0.96; P = .04). In the subgroup of primary cytoreductive surgery, median progression-free survival was 29.7 (IQR, 17.2-90.1 months) in the control group and 23.9 months (IQR, 12.3-71.5 months) in the HIPEC group, and the median overall survival was not reached in the control group and 71.3 months (IQR, 45.6 months to not reported) in the HIPEC group. Conclusions and Relevance: The addition of HIPEC to cytoreductive surgery did not improve progression-free and overall survival in patients with advanced epithelial ovarian cancer. Although the results are from a subgroup analysis, the addition of HIPEC to interval cytoreductive surgery provided an improvement of progression-free and overall survival. Trial Registration: ClinicalTrials.gov Identifier: NCT01091636.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamasurg.2022.0143

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 221

Metadata

Authors
Lim, M. C., Chang, S.-J., Park, B., Yoo, H. J., Yoo, C. W., Nam, B. H., Park, S.-Y., Collaborators, H. F. O. C., Seo, S.-S., Kang, S., Yun, J. Y., Cho, D.-S., Kim, S. H., Kim, T.-S., Park, S. S., Lee, D. W., Park, S. C., Park, H. M., Han, S.-S., Kim, S. H., Yang, H. C., Kim, M. S., Lee, J. M., Eom, B. W., Kim, Y. I., Yoon, H. M., Choi, I. J., Kim, S. H., Joung, J. Y., Seo, H. K., Joo, J. N., Song, Y. J., Park, S. H., Jung, D. C., Kim, M. J., Park, J. W., Jeong, S.-Y., Yun, Y. H., Park, S., & Bristow, R. E.
Venue
JAMA Surgery
Published
2022-05-01
Volume
157
Issue
5
Pages
374
ISSN
2168-6254 (ISSN-L)
OpenAlex
W4220935310
Cited by
221
References
4
FWCI
32.85
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamasurg.2022.0143
The paper
Lim, M. C., Chang, S.-J., Park, B., Yoo, H. J., Yoo, C. W., Nam, B. H., Park, S.-Y., Collaborators, H. F. O. C., Seo, S.-S., Kang, S., Yun, J. Y., Cho, D.-S., Kim, S. H., Kim, T.-S., Park, S. S., Lee, D. W., Park, S. C., Park, H. M., Han, S.-S., . . . Bristow, R. E. (2022). Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. JAMA Surgery. https://doi.org/10.1001/jamasurg.2022.0143

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.